Received Feb 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
Chills; Nausea; Headache; This non-serious case was reported by a physician via call center representative and described the occurrence of chills in a patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced chills (Verbatim: Chills), nausea (Verbatim: Nausea) and headache (Verbatim: Headache). The outcome of the chills, nausea and headache were unknown. It was unknown if the reporter considered the chills, nausea and headache to be related to Shingrix. It was unknown if the company considered the chills, nausea and headache to be related to Shingrix. Additional Information: GSK Receipt Date: 23-JAN-2025 The reporter reported that the patient had adverse reactions to 1st dose of Shingrix and the symptoms included headache, nausea, and chills and wanted to knew if patient should be given the second dose